Search results for "embolism"

showing 10 items of 457 documents

Rare occurrence of Whipple Disease in a young female patient with a fatal outcome

2013

Abstract Whipple Disease is a rare chronic multi-systemic disease caused by the ubiquitous environmental Gram-positive bacterium Tropheryma whipplei . It can be fatal if untreated. Here we describe the fatal outcome in a 27-year-old Caucasian female patient with a three-month history of persistent fever, anemia, weight loss and diarrhea. The final resolution of the diagnostic process was only reached after the patient’s death thanks to autopsy. The case depicted is a classic Whipple Disease histologically characterized by digestive involvement based on positive periodic acid-Schiff (PAS) staining and immunohistochemical analysis for T. whipplei and systemic involvement (pericarditis, brain …

medicine.medical_specialtyPathologyForensic pathologyHealth (social science)AnemiaEpidemiologyAutopsyDiseasePathology and Forensic MedicineForensic pathologyTropheryma whippleiPericarditisSettore MED/43 - Medicina LegalemedicineFat embolismPost-mortem diagnosisbiologybusiness.industryWhipple DiseasePost-mortem diagnosibiology.organism_classificationmedicine.diseaseDermatologyImmunohistochemistryTropheryma whippleibusinessLawWhipple Disease
researchProduct

Inter-relationship between platelet-derived microparticles and oxidative stress in patients with venous thromboembolism

2020

Background: Hypercoagulative conditions play a key role in venous thromboembolism (VTE). Inflammation is currently linked to VTE, but the potential role of circulating microparticles and oxidative stress (OxS) must be elucidated. The aim of this study was to evaluate platelet-derived microparticles and surrogate OxS biomarkers in patients diagnosed with VTE through a case&ndash

medicine.medical_specialtyPhysiologyThiobarbituric acidvenous thromboembolismClinical Biochemistry030204 cardiovascular system & hematologymedicine.disease_causeBiochemistryGastroenterologyPathophysiologyArticleSuperoxide dismutase03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePlatelet degranulationInternal medicinemedicineTBARSoxidative stressPlateletcardiovascular diseases030212 general & internal medicineMolecular BiologymicroparticlesVenous thromboembolism.biologybusiness.industrylcsh:RM1-950PlateletbiomarkersCell BiologyBiomarkerequipment and suppliesMalondialdehydelcsh:Therapeutics. PharmacologyClotting timechemistryMicroparticleplateletsbiology.proteinOxidative strebusinessOxidative stress
researchProduct

Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias an…

2012

Hypertension is the most common cardiovascular disorder and atrial fibrillation is the most common clinically significant arrhythmia. Both these conditions frequently coexist and their prevalence increases rapidly with aging. There are different risk factors and clinical conditions predisposing to the development of atrial fibrillation, but due its high prevalence, hypertension is still the main risk factor for the development of atrial fibrillation. Several pathophysiologic mechanisms (such as structural changes, neurohormonal activation, fibrosis, atherosclerosis, etc.) have been advocated to explain the onset of atrial fibrillation. The presence of atrial fibrillation per se increases th…

medicine.medical_specialtyPhysiologymacromolecular substancesFibrosisRisk FactorsCardiovascular DisorderInternal medicineThromboembolismAtrial FibrillationInternal MedicinemedicineHumanscardiovascular diseasesRisk factorStrokeSocieties Medicalbusiness.industryWarfarinAtrial fibrillationHypertension atrial fibrillation anticoagulants antihypertensive treatmentMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREmedicine.diseaseThrombosisEuropeBlood pressureHypertensionCardiologyCardiology and Cardiovascular Medicinebusinessmedicine.drugJournal of hypertension
researchProduct

Thrombosis

2014

Background— Thrombosis is the common pathology underlying ischemic heart disease, ischemic stroke, and venous thromboembolism (VTE). The Global Burden of Disease Study 2010 (GBD 2010) documented that ischemic heart disease and stroke collectively caused 1 in 4 deaths worldwide. GBD 2010 did not report data for VTE as a cause of death and disability. Objective— To review the literature on the global burden of disease caused by VTE. Approach and Results— We performed a systematic review of the literature on the global disease burden because of VTE in low-, middle-, and high-income countries. Studies from Western Europe, North America, Australia, and Southern Latin America (Argentina) yielded…

medicine.medical_specialtyPopulation ageingPopulationMyocardial IschemiaDisease030204 cardiovascular system & hematologyGlobal HealthCohort Studies03 medical and health sciencesLife Expectancy0302 clinical medicineCost of IllnessCause of DeathEnvironmental healthGlobal healthPrevalenceHumansMedicinecardiovascular diseases030212 general & internal medicineIntensive care medicineeducationStrokeDisease burdenCause of deathVenous Thrombosiseducation.field_of_studybusiness.industryIncidenceIncidence (epidemiology)Racial GroupsAge FactorsThrombosisVenous ThromboembolismHematologymedicine.diseaseThrombosis3. Good healthStrokePneumoniaVenous thrombosisSocial ClassQuality-Adjusted Life YearsMedical emergencyPulmonary EmbolismCardiology and Cardiovascular MedicinebusinessArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Prevention of venous thromboembolic events occurring in myeloma patients treated with second-generation novel agents

2021

Thrombosis and neoplasms are strictly linked, and the diagnosis of a malignancy is a relevant risk factor for venous thromboembolism (VTE). In particular, between gammopathies, the VTE risk is known to be increased in both monoclonal gammopathy of uncertain significance and in multiple myeloma, with a 3- and 9-fold increase respectively, when compared to the general population. The risk appears to be further increased in patients treated with immunomodulating drugs, such as thalidomide, especially when in combination with dexamethasone or conventional cytotoxic chemotherapies, and lenalidomide. In 2008 the International Myeloma Working Group put out thrombosis prophylaxis recommendations fo…

medicine.medical_specialtyPopulationAntineoplastic Agents030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciencesAntineoplastic Agents Immunological0302 clinical medicineFibrinolytic AgentsRisk FactorsInternal medicinemedicineHumansImmunologic FactorsRisk factoreducationMultiple myelomaLenalidomideeducation.field_of_study030219 obstetrics & reproductive medicinebusiness.industryWarfarinAnticoagulantsVenous ThromboembolismGeneral MedicineEvidence-based medicinemedicine.diseaseThrombosisPrevention and controlThalidomideTreatment OutcomeMultiple MyelomabusinessProteasome Inhibitorsmedicine.drugPanminerva Medica
researchProduct

Predicting Venous Thromboembolism in Primary Care

2020

medicine.medical_specialtyPrimary Health Carebusiness.industryPrimary health careMEDLINEAnticoagulantsVenous ThromboembolismHematologyPrimary careRisk FactorsmedicineHumansIntensive care medicinebusinessVenous thromboembolismThrombosis and Haemostasis
researchProduct

Primary thromboembolic prevention in multiple myeloma patients: An exploratory meta-analysis on aspirin use

2018

Background: Multiple myeloma (MM) is a common hematological disorder, often complicated by venous thromboembolism, especially during treatment with immunomodulatory drugs. Acetylsalicylic acid (ASA) has been extensively used as thromboprophylaxis but its rationale is unclear and the efficacy versus low-molecular weight heparins (LMWH) is still matter of debate. European and American guidelines suggest different approaches and the optimal antithrombotic strategy is yet to be established. Methods: We conducted an exploratory metanalysis and a systematic review on studies comparing ASA versus other interventions for thromboprophylaxis (no intervention or LMWH) in patients with MM. Results: Ten…

medicine.medical_specialtyPsychological intervention030204 cardiovascular system & hematologyLower risknot knownlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineAntithromboticHumansMedicineMultiple myelomaRetrospective StudiesAspirinAspirinbusiness.industryAnti-Inflammatory Agents Non-SteroidalRetrospective cohort studyVenous ThromboembolismHematologymedicine.diseaseSurgery030220 oncology & carcinogenesisMeta-analysisMultiple Myelomabusinessmedicine.drugSeminars in Hematology
researchProduct

Edoxaban for pulmonary embolism with right ventricular dysfunction

2016

medicine.medical_specialtyPyridinesbusiness.industryVentricular Dysfunction RightVenous ThromboembolismHematology030204 cardiovascular system & hematologymedicine.diseaseRight ventricular dysfunctionPulmonary embolismThiazoles03 medical and health scienceschemistry.chemical_compound0302 clinical medicineText miningchemistryEdoxabanInternal medicinemedicineCardiologyHumans030212 general & internal medicinePulmonary EmbolismbusinessThe Lancet Haematology
researchProduct

Risk of Recurrence After a First Episode of Symptomatic Venous Thromboembolism Provoked by a Transient Risk Factor A Systematic Review

2010

Background We aimed to determine the risk of recurrence for symptomatic venous thromboembolism (VTE) provoked by different transient risk factors. Data Sources MEDLINE, EMBASE, and Cochrane Collaboration Registry of Randomized Trials databases were searched. Study Selection Prospective cohort studies and randomized trials of patients with a first episode of symptomatic VTE provoked by a transient risk factor and treated for at least 3 months were identified. Data Extraction Number of patients and recurrent VTE during the 0- to 12-month and 0- to 24-month intervals after stopping therapy, study design, and provoking risk factor characteristics were extracted. Data Synthesis Annualized recurr…

medicine.medical_specialtyRate ratioRisk Assessmentlaw.inventionRandomized controlled triallawRecurrenceRisk FactorsInternal medicineEpidemiologyInternal MedicinemedicineHumansRisk factorProspective cohort studyFirst episodebusiness.industryIncidence (epidemiology)IncidenceVenous Thromboembolismvenous thrombosis recurrent eventmedicine.diseasePrognosisSurgeryVenous thrombosisbusiness
researchProduct

Cardiac arrest in special circumstances

2021

Purpose of review European Resuscitation Council Guidelines for Cardiopulmonary Resuscitation prioritize treatments like chest compression and defibrillation, known to be highly effective for cardiac arrest from cardiac origin. This review highlights the need to modify this approach in special circumstances. Recent findings Potentially reversible causes of cardiac arrest are clustered into four Hs and four Ts (Hypoxia, Hypovolaemia, Hyperkalaemia/other electrolyte disorders, Hypothermia, Thrombosis, Tamponade, Tension pneumothorax, Toxic agents). Point-of-care ultrasound has its role in identification of the cause and targeting treatment. Time-critical interventions may even prevent cardiac…

medicine.medical_specialtyResuscitationDefibrillationbusiness.industrymedicine.medical_treatmentWater-Electrolyte ImbalanceHypothermiaHypothermiaReturn of spontaneous circulationCritical Care and Intensive Care Medicinemedicine.diseaseThrombosisCardiopulmonary ResuscitationHeart ArrestPulmonary embolismPregnancymedicineHumansFemaleTamponadeCardiopulmonary resuscitationmedicine.symptomIntensive care medicinebusinessOut-of-Hospital Cardiac ArrestCurrent Opinion in Critical Care
researchProduct